Technology | Nuclear Imaging | October 14, 2015

Gamma Medica Receives CE Mark for LumaGEM Molecular Breast Imaging System

Approval brings patients in Europe one step closer to improved screening for dense breast tissue

Gamma Medica, LumaGEM MBI system, molecular breast imagign, CE Mark approval

Image courtesy of Gamma Medica

October 14, 2015 — Gamma Medica Inc. announced the CE Mark approval allowing for the sale and distribution of the LumaGEM Molecular Breast Imaging (MBI) system within the European Economic Area (EEA). Gamma Medica is finalizing distribution partners in strategic markets across the EEA.

Breast cancer is the most common cancer affecting women in Europe, with nearly one in 10 women developing breast cancer before the age of 80. Dense breast tissue has been linked to an increased risk of breast cancer and a decrease in mammography sensitivity. These factors impact early detection efforts as both cancer and dense tissue appear white on the mammogram.

The LumaGEM MBI system addresses the critical shortcomings of mammography and other screening modalities in the early detection of breast cancer for the 50 percent of women with dense breast tissue. The system has been commercially available in the United States since obtaining approval by the U.S. Food and Drug Administration (FDA) in 2011.

A recent study conducted by Mayo Clinic, and published in two articles in the American Journal of Roentgenology (AJR) in 2015 determined that the addition of MBI, such as the LumaGEM MBI system, to an annual mammogram screening demonstrated a near 400 percent increase in invasive breast cancer detection rates. The combination also demonstrated a 50 percent reduction in biopsies and a subsequent 15 percent lower cost per cancer detected than screening with mammography alone.

The growing awareness of the limitations of mammography screening for women with dense breast tissue and the necessity for an effective adjunct screening technology led to the creation of LumaGEM MBI. Unlike mammography, tomosynthesis, ultrasound and magnetic resonance imaging (MRI) — all of which are anatomical imaging tests — MBI is a functional imaging modality that highlights metabolic activity in the breast and detects tumors not visible on a mammogram due to tissue density.

It is important for women to discuss with their doctors if MBI is an appropriate screening method for them. In addition to women with dense breast tissue or suspicious lesions, MBI may also be valuable for high-risk patients with a family history of breast cancer, patients who have tested positive for BRCA1 or BRCA2 genes, symptomatic patients, patients with cosmetic augmentation or patients who cannot receive an MRI.

For more information: www.gammamedica.com

Related Content

Partners HealthCare Chooses Visage 7 for Enterprise Imaging
News | Enterprise Imaging | January 18, 2019
Visage Imaging Inc. announced the signing of Partners HealthCare, the largest health system in Massachusetts, for...
Novel Technique May Significantly Reduce Breast Biopsies
News | Breast Biopsy Systems | January 17, 2019
A novel technique that uses mammography to determine the biological tissue composition of a tumor could help reduce...
Philips Launches Azurion With FlexArm
Technology | Angiography | January 17, 2019
Philips announced the launch of Azurion with FlexArm, designed to enhance positioning flexibility for image-guided...
NewYork-Presbyterian Hospital Partners With Philips for Health IT and Clinical Informatics
News | Enterprise Imaging | January 16, 2019
Philips announced that NewYork-Presbyterian Hospital has chosen to implement the company’s IntelliSpace Enterprise...
Digital Mammography Increases Breast Cancer Detection
News | Mammography | January 16, 2019
The shift from film to digital mammography increased the detection of breast cancer by 14 percent overall in the United...
MIM Software Inc. Receives FDA 510(k) Clearance for Molecular Radiotherapy Dosimetry
Technology | Nuclear Imaging | January 16, 2019
MIM Software Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for molecular radiotherapy...
Artificial Intelligence Used in Clinical Practice to Measure Breast Density
News | Artificial Intelligence | January 15, 2019
An artificial intelligence (AI) algorithm measures breast density at the level of an experienced mammographer,...
Sponsored Content | Videos | Artificial Intelligence | January 15, 2019
ITN Contributing Editor Greg Freiherr offers an overview of...
Sponsored Content | Videos | Enterprise Imaging | January 14, 2019
ITN Contributing Editor Greg Freiherr offers an overview of enterprise
Videos | Interventional Radiology | January 11, 2019
Julius Chapiro, M.D., research faculty member and an...